MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

INTERPACE BIOSCIENCES, INC. (IDXG)

INTERPACE BIOSCIENCES, INC. (IDXG)

|||

Cash Flow Overview

Change in Cash
$41K
Free Cash flow
$41K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Accounts payable
    • Accrued salaries and bonus
    • Lab supplies write-off
    • Others
Negative Cash Flow Breakdown
    • Other current assets
    • Accounts receivable
    • Operating lease liabilities
    • Purchase of property and equipme...
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Payments made on note payable
0
-
1,000
900
Series c conversion costs
0
-
0
0
Cash paid for repurchase of restricted shares
-
-
18
-
Net cash used in financing activities
0
-
-1,018
-900
Amortization of deferred financing fees
0
-
16
16
Asset impairment - lab supplies
0
-
0
0
Change in fair value of note payable
0
-
-23
-105
Depreciation and amortization
127
118
118
111
Deferred taxes
62
277
-21,254
-
Amortization on operating lease right of use asset
109
107
103
100
Accounts receivable
386
276
-317
-1,265
Other current assets
795
-355
21
-14
Other long-term assets
-
-
1
-
Accounts payable
374
-47
-390
-8
Accrued salaries and bonus
238
-1,172
456
-601
Accrued liabilities
-
-
-273
-
Other accrued expenses
15
601
-
16
Operating lease liabilities
-133
-130
-99
-98
Other long-term liabilities
108
110
95
100
Stock-based compensation
4
4
4
7
Net income
158
721
22,657
911
Lab supplies write-off
217
-
-
-
Net cash provided by operating activities
98
283
2,138
1,938
Purchase of property and equipment
57
141
38
117
Net cash used in investing activities
-57
-141
-38
-117
Net increase (decrease) in cash and cash equivalents
41
142
1,082
921
Cash and cash equivalents beginning
2,647
2,505
1,423
1,461
Cash and cash equivalents ending
2,688
2,647
2,505
1,423
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Accounts payable$374K (191.44%↑ Y/Y)Accrued salaries andbonus$238K (235.23%↑ Y/Y)Lab supplieswrite-off$217K Net income$158K (-84.31%↓ Y/Y)Depreciation andamortization$127K (-35.20%↓ Y/Y)Amortization on operatinglease right of use...$109K (-43.52%↓ Y/Y)Other long-termliabilities$108K (-49.53%↓ Y/Y)Deferred taxes$62K Other accruedexpenses$15K (103.74%↑ Y/Y)Stock-based compensation$4K (-83.33%↓ Y/Y)Net cash provided byoperating activities$98K (-94.42%↓ Y/Y)Canceled cashflow$1,314K Net increase(decrease) in cash and cash...$41K (104.28%↑ Y/Y)Canceled cashflow$57K Other current assets$795K (250.22%↑ Y/Y)Accounts receivable$386K (129.40%↑ Y/Y)Operating leaseliabilities-$133K (28.11%↑ Y/Y)Net cash used ininvesting activities-$57K (71.64%↑ Y/Y)Purchase of property andequipment$57K (-71.64%↓ Y/Y)